Pomerantz LLP investigates Telix Pharmaceuticals on securities fraud claims.

Pomerantz LLP is investigating claims of securities fraud against Telix Pharmaceuticals Limited. The investigation concerns the company's disclosures regarding the development of its prostate cancer therapeutic candidates. After Telix disclosed receipt of a subpoena from the SEC, its ADR price fell 10.44% to $14.58. Investors who purchased Telix securities are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980 to discuss their options.

Pomerantz LLP has initiated an investigation into claims of securities fraud against Telix Pharmaceuticals Limited (TLX). The probe focuses on the company's disclosures regarding the development of its prostate cancer therapeutic candidates. The investigation was sparked by Telix's revelation of a subpoena from the U.S. Securities and Exchange Commission (SEC) on July 22, 2025, seeking documents and information related to the development of these candidates.

Following the disclosure, Telix's American Depositary Receipt (ADR) price fell sharply, dropping by 10.44% to $14.58. This significant decrease in share value has prompted investors to seek clarification and potential recourse. Investors who purchased Telix securities are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, to discuss their options and potential involvement in the class action.

The investigation by Pomerantz LLP aims to determine whether Telix and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices [1]. Separately, national shareholders rights firm Hagens Berman has also opened an investigation into whether Telix may have misled investors about the development and commercial prospects of its candidates [2].

Investors affected by this situation are encouraged to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, to discuss potential involvement in the class action [1]. For further information or to submit losses, investors can visit www.hbsslaw.com/investor-fraud/tlx or contact Reed Kathrein at TLX@hbsslaw.com or 844-916-0895 [2].

References:
[1] https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-telix-pharmaceuticals-limited--tlx-302521589.html
[2] https://www.globenewswire.com/news-release/2025/08/08/3130343/32716/en/Telix-Pharmaceuticals-Limited-TLX-Shares-Fall-Amid-SEC-Subpoena-Hagens-Berman.html